GLAUKOS CORP (GKOS)
US3773221029 - Common Stock
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Glaukos (NYSE:GKOS) just reported results for the first quarter of 2024.Glaukos...
Glaukos Announces First Quarter 2024 Financial Results
Glaukos Announces the Release of its 2023 Sustainability Report
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
Glaukos says 2023 revenue to be in excess of $313M (NYSE:GKOS)
Glaukos (NYSE:GKOS) said Tuesday that its preliminary total net sales for the fourth quarter and fiscal 2023 are expected to be in excess of $81 million and...
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
JP Morgan raises Glaukos to buy; cites potential of iDose, iStent (NYSE:GKOS)
JP Morgan raised its rating of Glaukos (GKOS) to overweight, citing the company’s recently approved ophthalmology product iDose. The investment bank said it was
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
Interesting GKOS Put And Call Options For February 2024
Notable Thursday Option Activity: HSY, AEHR, GKOS
Glaukos stock jumps 15% on FDA approval of glaucoma drug (NYSE:GKOS)
Glaukos (GKOS) stock soared 15% after the FDA approved its drug iDose TR for treatment of glaucoma and the company issued 2024 sales guidance. Read more here.
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
Bullish Two Hundred Day Moving Average Cross - GKOS
Truist starts Glaukos at buy, cites glaucoma market opportunity (GKOS)
Truist has initiated coverage of Glaukos (GKOS) with a buy rating, citing the company’s glaucoma treatment iDose, which is currently being reviewed by the FDA. Read more here.
Wells Fargo upgrades Glaukos to overweight, cites positive catalysts (GKOS)
Wells Fargo upgraded Glaukos (GKOS) to overweight, citing positive catalysts and reimbursement developments, along with its iDose pipeline product. Read more here.
Glaukos Announces Participation in Stifel Healthcare Conference
Glaukos Announces Third Quarter 2023 Financial Results
Notable Wednesday Option Activity: GKOS, VFC, VIRT
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting